Board of directors
|
Jonas Ekblom
Executive Chairman Born 1965. Active in the company since 2024. Jonas has a bachelor's degree in chemistry from Stockholm University, a doctorate in medical sciences from Uppsala University and a postdoctoral education from the University of Southern California in Los Angeles, USA. Since 1996, Jonas holds an associate professorship in pharmacology at Uppsala University. Jonas has worked for three decades in research and development of pharmaceutical and medtech products. Jonas has held board and management positions in public and privately held life science companies in Sweden, Switzerland and the USA. He has served as CEO of BOWS Pharmaceuticals SA, Pergamum AB and Promore Pharma AB. Today, Jonas is chairman of the board in Oblique Therapeutics AB (publ.) and partner in Ekblom & Denissenko.
Shareholding: 0 shares. Independent in relation to the company and the owners.
|
|
Isabelle Ducellie
Born 1969. Active in the company since 2025. Isabelle Ducellier is a dual citizen of France and Sweden. She has over 30 years of experience in building global brands in highly international environments. She began her career in the wine and spirits industry but has focused on consumer health since 2017. She has served as Secretary General of the Swedish Childhood Cancer Fund, CEO of the world-leading probiotic company BioGaia, and most recently CEO of Orkla Health—a key European player in VMS (Vitamins, Minerals, and Supplements), oral health, and a global manufacturer of wound care and first aid products.
Shareholding: 2222 shares. Independent in relation to the company and the owners. |
|
Otto Skolling
Born 1961. Active in the company since 2025. Otto has over 30 years of experience in product development, business development, and project management in the pharmaceutical and medical technology industries, with leading roles at companies such as Novozymes, Siemens Life Support Systems, and Pharmacia Upjohn. He has also been the chairman of the board at Volusense AS and a board member at several companies including Asarina Pharma AB and Nanexa AB. Otto holds a master's degree in chemical engineering from KTH. Otto is currently the chairman of the board at Chordate Medical Holding AB and Pharmor AB, as well as a board member at Lipidor AB, Respinor AB (Publ), and Isles of Wines AB. He also works with business development for Dilafor AB.
Shareholding: 0 shares. Independent in relation to the company and the owners. |
![]() |
Nikolaj Sørensen
Born 1972. Board members since 2021. Nikolaj Sörensen has more than 20 years of experience from the life science and the pharmaceutical industry in Sweden and abroad. Nikolaj today serves as President and CEO of Orexo AB. Previous appointments includes senior management positions at Pfizer and as management consultant at the Boston Consulting Group (BCG). Nikolaj has a M.Sc. in International Business from Copenhagen Business School. Nikolaj is Board member of Gesynta Pharma AB. Shareholding: 28 902 shares. independent from the company and owners. |
![]() |
Richard Ding Born 1982. Active in the company since 2025. Richard has more than 15 years of experience in global equity investment and maximizing shareholder value. Richard is also a serial entrepreneur who has co-founded, acquired and developed multiple businesses across finance, direct-to-consumer (DTC) goods, and healthcare. Richard currently serves as the CEO of How100.ai and Goldenwise Capital Group, as well as the Managing Director of BalanceGenics and The Stretching Institute of America. Richard holds an M.Sc. in Financial Mathematics from the University of British Columbia, Canada. Shareholding: 2.713.938 shares. Independent in relation to the Company and the owners. |
Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.